North America Immunohistochemistry Market

North America Immunohistochemistry Market Size (2022 to 2027)

As per our report, the size of the North America Immunohistochemistry Market has been estimated at USD 570.28 million in 2022. It is further estimated to be growing at a CAGR of 7.6% and worth USD 822.53 million by 2027.

The market is expected to show substantial growth during the forecast period as well as in the future years. Immunohistochemistry is a medical procedure that includes staining on a fresh or stored cancer tissue that is removed out during biopsy. This technique assists in the detection of hormone receptors on the surface of cancer cells. Immunohistochemistry is majorly used for the diagnosis of cancers, especially tumor antibodies.

The growth of technology in the biotech market and sudden commercialization are the major drivers for the growth of the market in this region.

The growth is hampered because of its requirement for extremely high capital and long R & D activities. But, the increasing adoption of immunohistochemistry products for the detection of tumors of unknown origin is leading to North America’s dominance.

This research report on North America Immunohistochemistry Market has been segmented and sub-segmented into the following categories:

By Product: 

• Antibodies
• Reagents
• Equipment
• Kits

By Application: 

• Diagnostics
• Drug Testing

By End User: 

• Hospitals
• Diagnostic Laboratories
• Research Institutes

By Country: 

• The United States
• Canada
• Rest of North America

Key Participants dominating the North American Immunohistochemistry Market Profiled in the Report are F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.